Abstract Library

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

1

Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis

Front Immunol. 2022 Oct 26;13:1040725. doi: 10.3389/fimmu.2022.1040725. eCollection 2022.

 

Natalie Frede 1Eva Rieger 1Raquel Lorenzetti 1Alexandra Nieters 2Ana C Venhoff 1Carolin Hentze 1Marcus von Deimling 1Nora Bartholomä 1Jens Thiel 1 3Reinhard E Voll 1Nils Venhoff 1

2

The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership

Rheumatology (Oxford). 2022 Dec 1;keac676.doi: 10.1093/rheumatology/keac676.Online ahead of print.

 

Louise Hailey 1Chris Bundy 2Helen Burstow 3David Chandler 4Russ Cowper 5Philip Helliwell 6Lucille Joannes 7Andy Kelly 8Bronagh Kennedy 9Suzannah Kinsella 10Helen McAteer 11Sandeep Mukherjee 3Jon Packham 12 13Elspeth Wise 14Helen Young 15Laura C Coates 1

3

Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

J Rheumatol. 2022 Nov 1;jrheum.220316. doi: 10.3899/jrheum.220316. Online ahead of print.

 

Kristina Callis Duffin 1Luis Daniel Mazzuoccolo 1María Julia Cura 1Maria Esposito 1Anthony P Fernandez 1Paolo Gisondi 1Alessandro Giunta 1Tom Hillary 1Stefano Piaserico 1James Solomon 1Joseph F Merola 1

4

Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Skin Health Dis. 2022 Jul 6;2(4):e149. doi: 10.1002/ski2.149. eCollection 2022 Dec.

 

Georgia Lada 1 2Hector Chinoy 3Peter S Talbot 2Richard B Warren 1C Elise Kleyn 1BADBIR Study Group

5

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study

Patient. 2022 Nov;15(6):657-668. doi: 10.1007/s40271-022-00588-6.Epub 2022 Jun 30.

 

Ana-Maria Orbai 1Laura C Coates 2Atul Deodhar 3Philip S Helliwell 4Christopher T Ritchlin 5Evan Leibowitz 6Alexa P Kollmeier 7Elizabeth C Hsia 7 8Xie L Xu 7Shihong Sheng 7Yusang Jiang 7 9Yan Liu 7Chenglong Han 7

6

Biomarkers in psoriatic arthritis: A meta-analysis and systematic review

Front Immunol. 2022 Nov 30;13:1054539.doi: 10.3389/fimmu.2022.1054539. eCollection 2022.

 

Theo Wirth 1Nathalie Balandraud 1 2Laurent Boyer 3Pierre Lafforgue 1Thao Pham 1

7

What's new and what's next for biological and targeted synthetic treatments in psoriatic arthritis?

Expert Opin Biol Ther. 2022 Dec;22(12):1545-1559.doi: 10.1080/14712598.2022.2152321. Epub 2022 Dec 5.

 

Flavia Sunzini 1Arianna D'Antonio 2Mauro Fatica 2Paola Triggianese 2Paola Conigliaro 2Elisabetta Greco 2Alberto Bergamini 2Maria Sole Chimenti 2

8

Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

J Rheumatol. 2022 Nov 1;jrheum.220309. doi: 10.3899/jrheum.220309. Online ahead of print.

 

Ennio Lubrano 1Jon Chan 1Ruben Queiro-Silva 1Alberto Cauli 1Niti Goel 1Denis Poddubnyy 1Peter Nash 1Dafna D Gladman 1

9

Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors

 Rheumatol. 2022 Nov 15;jrheum.220908. doi: 10.3899/jrheum.220908. Online ahead of print.

 

Timothy S H Kwok 1Mitchell Sutton 1Richard J Cook 1Daniel Pereira 1Vinod Chandran 1Dafna D Gladman 1

10

An overview of psoriatic arthritis including clinical manifestations, assessment, diagnostic criteria, investigations, drug management and GRAPPA guidelines

Musculoskeletal Care. 2022 Nov;20 Suppl 1:S2-S11. doi: 10.1002/msc.1693.

 

Jonathan Packham 1 2Bilal Tarar 1

11

Outcome measures in psoriatic arthritis: Where next?

Musculoskeletal Care. 2022 Nov;20 Suppl 1:S22-S31. doi: 10.1002/msc.1692.

 

Simon Hackett 1Laura C Coates 1

12

The role of the multidisciplinary team in the management of psoriatic arthritis

Musculoskeletal Care. 2022 Nov;20 Suppl 1:S32-S40. doi: 10.1002/msc.1690.

 

Deepak R Jadon 1Philip S Helliwell 2

13

The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis

Musculoskeletal Care. 2022 Nov;20 Suppl 1:S12-S21. doi: 10.1002/msc.1694.Epub 2022 Sep 7.

 

George E Fragoulis 1 2Stefan Siebert 2

14

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

Pharmacogenomics J. 2022 Oct 15. doi: 10.1038/s41397-022-00290-8.Online ahead of print.

 

Philippa D K Curry 1Andrew P Morris 1Anne Barton 1 2James Bluett 3 4

15

Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis

Ann Rheum Dis. 2022 Oct 19;annrheumdis-2022-222787. doi: 10.1136/ard-2022-222787.Online ahead of print.

 

Irina Gessl 1Claudia A Hana 1Thomas Deimel 1Martina Durechova 1Miriam Hucke 2Victoria Konzett 1Mihaela Popescu 3Paul Studenic 1 4Gabriela Supp 1Michael Zauner 1Josef S Smolen 1Daniel Aletaha 1Peter Mandl 5

16

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

J Rheumatol. 2022 Oct 15;jrheum.220315. doi: 10.3899/jrheum.220315. Online ahead of print.

 

Ying-Ying Leung 1Tatiana V Korotaeva 1Liliana Candia 1Susanne Juhl Pedersen 1Wilson Bautista Molano 1Eric M Ruderman 1Radjesh Bisoendial 1Rodolfo Perez-Alamino 1Wendy Olsder 1Burkhard Möller 1Simeon Grazio 1Tania Gudu 1Girish M Mody 1Carlos Pineda 1Helena Raffayova 1Sherry Rohekar 1Claudia Goldenstein-Schainberg 1Sergio R Gutierrez Urena 1Julio César Casasola Vargas 1Bhowmik Meghnathi 1Roopa Prasad 1Pascal Richette 1Jose Roberto S Miranda 1Nikolas Malliotis 1Ulla Lindqvist 1David Simon 1Amara Ezeonyeji 1Enrique R Soriano 1Oliver FitzGerald 1

17

Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis

Rheumatology (Oxford). 2022 Oct 6;61(10):4119-4123. doi: 10.1093/rheumatology/keac025.

 

Michelle L M Mulder 1 2Anouk M Bertram 1 3Mark H Wenink 1Johanna E Vriezekolk 1 3

18

Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis

Int J Rheum Dis. 2022 Oct 2. doi: 10.1111/1756-185X.14447. Online ahead of print.

 

Patricia Harkins 1Eoghan Burke 2Catherine Swales 1Alan Silman 1Richard Conway 3

19

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Drugs Real World Outcomes. 2022 Oct 15. doi: 10.1007/s40801-022-00326-2.Online ahead of print.

 

Philip J Mease 1Alexis Ogdie 2Soumya D Chakravarty 3 4Natalie J Shiff 3 5Iris Lin 3Robert R McLean 6Wendi Malley 6Rebecca L Spitzer 6Arthur Kavanaugh 7Joseph F Merola 8

20

Advanced genomics and clinical phenotypes in psoriatic arthritis

Semin Immunol. 2022 Oct 25;101665. doi: 10.1016/j.smim.2022.101665.Online ahead of print.

 

Matteo Vecellio 1Stefano Rodolfi 2Carlo Selmi 3

21

Sex-Specific Differences in Patients with Psoriatic Arthritis: A Systematic Review

J Rheumatol. 2022 Oct 15;jrheum.220386. doi: 10.3899/jrheum.220386. Online ahead of print.

 

Laura C Coates 1Irene van der Horst-Bruinsma 2Ennio Lubrano 3Steph Beaver 4Emma Drane 5Baran Ufuktepe 6Alexis R Ogdie 7

22

Retention rate of secukinumab in psoriatic arthritis: Real-world data results from a Spanish multicenter cohort

Medicine (Baltimore). 2022 Sep 9;101(36):e30444.doi: 10.1097/MD.0000000000030444.

 

Marta Valero-Expósito 1María Martín-López 2Carlos Guillén-Astete 1Beatriz Joven 2Carolina Merino-Argumanez 3Valentina Emperiale 4Jose Campos 3Ana Pérez 4Javier Bachiller-Corral 1

23

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis

Rheumatology (Oxford). 2022 Sep 14;keac500. doi: 10.1093/rheumatology/keac500.Online ahead of print.

 

Philip J Mease 1Iain B McInnes 2Lai-Shan Tam 3Raji Rajalingam 4Steve Peterson 5Fareen Hassan 6Soumya D Chakravarty 7Christine Contré 8Alison Armstrong 4Wolf-Henning Boehncke 9Christopher Ritchlin 10

24

Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice

Ther Adv Musculoskelet Dis. 2022 Sep 5;14:1759720X221122417.doi: 10.1177/1759720X221122417. eCollection 2022.

 

Chrysoula G Gialouri 1Gerasimos Evangelatos 1Maria Pappa 1Anastasios Karamanakos 1Alexios Iliopoulos 2Maria G Tektonidou 1Petros P Sfikakis 1George E Fragoulis 3

25

Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling

Arthritis Rheumatol. 2022 Sep;74(9):1535-1543. doi: 10.1002/art.42154. Epub 2022 Aug 4.

 

Mehreen Soomro 1Michael Stadler 1Nick Dand 2James Bluett 3Deepak Jadon 4Farideh Jalali-Najafabadi 1Michael Duckworth 5Pauline Ho 3Helena Marzo-Ortega 6Philip S Helliwell 6Anthony W Ryan 7David Kane 8Eleanor Korendowych 9Michael A Simpson 2Jonathan Packham 10Ross McManus 11Cem Gabay 12Céline Lamacchia 13Michael J Nissen 13Matthew A Brown 14Suzanne M M Verstappen 15Tjeerd Van Staa 16Jonathan N Barker 5Catherine H Smith 17BADBIR Study GroupBSTOP study groupOliver FitzGerald 18Neil McHugh 19Richard B Warren 20John Bowes 3Anne Barton 3

 

Collaborators

Robert ChalmersCarsten FlohrKaren WatsonDavid Prieto-MerinoOras AlabasJonathan BarkerGabrielle BecherAnthony BewleyDavid BurdenSimon MorrisonPhil LawsIan EvansChristopher GriffithsShehnaz AhmedBrian KirbyElise KleynLinda LawsonTeena MackenzieTess McPhersonKathleen McElhoneRuth MurphyAnthony OrmerodCaroline OwenNick ReynoldsAmir RashidCatherine SmithRichard WarrenDavid BurdenCatherine SmithStefan SiebertSara BrownHelen McAteerJulia SchofieldNick Dand

26

Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice

Ther Adv Musculoskelet Dis. 2022 Sep 5;14:1759720X221122417.doi: 10.1177/1759720X221122417. eCollection 2022.

 

Chrysoula G Gialouri 1Gerasimos Evangelatos 1Maria Pappa 1Anastasios Karamanakos 1Alexios Iliopoulos 2Maria G Tektonidou 1Petros P Sfikakis 1George E Fragoulis 3

27

Does Age Matter in Psoriatic Arthritis? A Narrative Review

J Rheumatol. 2022 Oct;49(10):1085-1091. doi: 10.3899/jrheum.210349.Epub 2021 Aug 15.

 

George E Fragoulis 1Elena Nikiphorou 2Iain B McInnes 3Stefan Siebert 3

28

Body Composition in Patients With Psoriatic Arthritis and Changes During Interleukin-12/Interleukin-23 Inhibition

Arthritis Care Res (Hoboken). 2022 Oct;74(10):1608-1613. doi: 10.1002/acr.24623.Epub 2022 Jun 29.

 

Julien Paccou 1Wallis Bavière 1Elisabeth Sornay-Rendu 2Pawel Szulc 2Nassima Ramdane 1Bernard Cortet 1Roland Chapurlat 2René-Marc Flipo 1

29

Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study

JAMA Dermatol. 2022 Sep 14;e223682. doi: 10.1001/jamadermatol.2022.3682.Online ahead of print.

 

Dennis Freuer 1Jakob Linseisen 1 2Christa Meisinger 1

30

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations

Paediatr Drugs. 2022 Sep 28. doi: 10.1007/s40272-022-00533-y. Online ahead of print.

 

Jocelyn H Leu # 1Natalie J Shiff # 2 3Michael Clark 4Karen Bensley 4Kathleen G Lomax 4Katherine Berezny 4Robert M Nelson 5Honghui Zhou 4Zhenhua Xu 4

31

Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study

BMC Rheumatol. 2022 Sep 12;6(1):57. doi: 10.1186/s41927-022-00284-w.

 

Delia Colombo 1Micol Frassi 2Giusy Pagano Mariano 3Enrico Fusaro 4Claudia Lomater 5Patrizia Del Medico 6Florenzo Iannone 7Rosario Foti 8Massimiliano Limonta 9Antonio Marchesoni 10 11Bernd Raffeiner 12Ombretta Viapiana 13Walter Grassi 14Rosa Daniela Grembiale 15Giuliana Guggino 16Antonino Mazzone 17Enrico Tirri 18Roberto Perricone 19Pier Carlo Sarzi Puttini 20Salvatore De Vita 21Fabrizio Conti 22Alessandra Ori 23Lucia Simoni 23Martina Fiocchi 1Roberto Orsenigo 1Emanuela Zagni 24and the CHRONOS Study Group

 

Collaborators

and the CHRONOS Study Group: 

Micol FrassiMaurizio CaminitiEnrico FusaroClaudia LomaterPatrizia Del MedicoFlorenzo IannoneRosario FotiMassimiliano LimontaAntonio MarchesoniBernd RaffeinerOmbretta ViapianaWalter GrassiRosa Daniela GrembialeGiuliana GugginoAntonino MazzoneEnrico TirriRoberto PerriconePier Carlo Sarzi PuttiniSalvatore De VitaFabrizio Conti

32

Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience

J Rheumatol. 2022 Oct 1;jrheum.220333. doi: 10.3899/jrheum.220333. Online ahead of print.

 

Rosario Foti 1Elisa Visalli 1Giorgio Amato 1Ylenia Dal Bosco 1Roberta Foti 1Giacomo Baccano 1

33

Psoriatic arthritis: interaction between cardiometabolic diseases and inflammatory burden of the disease

Reumatol Clin (Engl Ed). 2022 Aug-Sep;18(7):387-392. doi: 10.1016/j.reumae.2021.05.003.Epub 2021 Nov 17.

 

José Andrés Lorenzo Martín 1Estefanía Pardo Campo 2Marina Pino Martinez 2María Colazo Burlato 3Manuel Rubén Queiro Silva 2

34

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Ann Rheum Dis. 2022 Aug 12;annrheumdis-2022-222849. doi: 10.1136/ard-2022-222849.Online ahead of print.

 

Hermine I Brunner 1Ivan Foeldvari 2Ekaterina Alexeeva 3Nuray Aktay Ayaz 4Inmaculada Calvo Penades 5Ozgur Kasapcopur 6Vyacheslav G Chasnyk 7Markus Hufnagel 8Zbigniew Zuber 9Grant Schulert 10Seza Ozen 11Adelina Rakhimyanova 12Athimalaipet Ramanan 13 14Christiaan Scott 15Betul Sozeri 16Elena Zholobova 17Ruvie Martin 18Xuan Zhu 18Sarah Whelan 19Luminita Pricop 18Alberto Martini 20Daniel Lovell 21Nicolino Ruperto 22Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

35

Psoriatic arthritis: one year in review 2022

Clin Exp Rheumatol. 2022 Sep;40(9):1611-1619.doi: 10.55563/clinexprheumatol/x3sfxe. Epub 2022 Sep 19.

 

Cosimo Cigolini 1Federico Fattorini 1Stefano Gentileschi 2Riccardo Terenzi 3Linda Carli 4

36

Sex- and gender-related differences in psoriatic arthritis

Nat Rev Rheumatol. 2022 Sep;18(9):513-526. doi: 10.1038/s41584-022-00810-7.Epub 2022 Aug 4.

 

Sanjana Tarannum 1Ying-Ying Leung 2Sindhu R Johnson 3Jessica Widdifield 4Vibeke Strand 5Paula Rochon 1Lihi Eder 6

37

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials

Rheumatol Ther. 2022 Aug;9(4):1181-1191. doi: 10.1007/s40744-022-00449-6.Epub 2022 May 23.

 

Philip Mease 1Arthur Kavanaugh 2Dafna Gladman 3 4Oliver FitzGerald 5Enrique R Soriano 6Peter Nash 7Dai Feng 8Apinya Lertratanakul 8Kevin Douglas 8Ralph Lippe 9Laure Gossec 10 11

38

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Br J Dermatol. 2022 Sep;187(3):438-441. doi: 10.1111/bjd.21233.Epub 2022 Jun 7.

 

Kristian Reich 1Xenophon Baraliakos 2Laura C Coates 3Boni Elewski 4Weibin Bao 5Torben Kasparek 6Corine Gaillez 6Effie Pournara 6Maher Aassi 6Chiara Perella 6Alice B Gottlieb 7

39

Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis

Ann Rheum Dis. 2022 Aug 16;annrheumdis-2022-222537. doi: 10.1136/ard-2022-222537.Online ahead of print.

 

Timothy S H Kwok 1Mitchell Sutton 2Daniel Pereira 2Richard J Cook 3Vinod Chandran 2 4Nigil Haroon 1 5Robert D Inman 1 6Dafna D Gladman 7 2

40

Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study

Ann Rheum Dis. 2022 Aug 3;annrheumdis-2022-222562. doi: 10.1136/ard-2022-222562.Online ahead of print.

 

Fabian Proft 1Susanne Lüders 2Theresa Hunter 3Gustavo Luna 4Valeria Rios Rodriguez 5Mikhail Protopopov 1Katharina Meier 6Georgios Kokolakis 6Kamran Ghoreschi 6Denis Poddubnyy 7

41

Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe

J Rheumatol. 2022 Aug 15;jrheum.220154. doi: 10.3899/jrheum.220154. Online ahead of print.

 

Laure Gossec 1Jessica A Walsh 1Kaleb Michaud 1Steve Peterson 1Elizabeth A Holdsworth 1Chetan S Karyekar 1Nicola Booth 1Soumya D Chakravarty 1Alexis Ogdie 1

42

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205-1218.doi: 10.1002/acr.24560. Epub 2022 Apr 29.

 

Brigitte Michelsen 1Stylianos Georgiadis 2Daniela Di Giuseppe 3Anne G Loft 4Michael J Nissen 5Florenzo Iannone 6Manuel Pombo-Suarez 7Herman Mann 8Ziga Rotar 9Kari K Eklund 10Tore K Kvien 11Maria J Santos 12Bjorn Gudbjornsson 13Catalin Codreanu 14Sema Yilmaz 15Johan K Wallman 16Cecilie H Brahe 17Burkhard Möller 18Ennio G Favalli 19Carlos Sánchez-Piedra 20Lucie Nekvindova 21Matija Tomsic 9Nina Trokovic 10Eirik K Kristianslund 11Helena Santos 22Thorvardur J Löve 23Ruxandra Ionescu 14Yavuz Pehlivan 24Gareth T Jones 25Irene van der Horst-Bruinsma 26Lykke M Ørnbjerg 17Mikkel Østergaard 27Merete L Hetland 28

43

Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination

Clin Exp Rheumatol. 2022 Jul;40(7):1432-1441.doi: 10.55563/clinexprheumatol/0jdyse. Epub 2021 Dec 7.

 

James Galloway 1Tim Raine 2Lucy Rivett 2Jacqueline Roberts 3Sally-Anne Dews 3Ernest H Choy 4

44

Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

Arthritis Rheumatol. 2022 Jul 13. doi: 10.1002/art.42280. Online ahead of print.

 

Laura C Coates 1Iain B McInnes 2Joseph F Merola 3Richard B Warren 4Arthur Kavanaugh 5Alice B Gottlieb 6Laure Gossec 7 8Deepak Assudani 9Rajan Bajracharya 9Jason Coarse 10Barbara Ink 9Christopher T Ritchlin 11

45

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

Rheumatology (Oxford). 2022 Jul 5;keac353. doi: 10.1093/rheumatology/keac353.Online ahead of print.

 

Philip J Mease 1Akihiko Asahina 2Dafna D Gladman 3Yoshiya Tanaka 4William Tillett 5Barbara Ink 6Deepak Assudani 6Christine de la Loge 7Jason Coarse 8Jason Eells 6Laure Gossec 9 10

46

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial

RMD Open. 2022 Jul;8(2):e002366. doi: 10.1136/rmdopen-2022-002366.

 

Philip S Helliwell 1Phillip J Mease 2Arthur Kavanaugh 3Laura C Coates 4Alexis Ogdie 5Atul Deodhar 6Vibeke Strand 7Gregory Kricorian 8Lyrica X H Liu 9David Collier 8Dafna D Gladman 10

47

Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort

Acta Derm Venereol. 2022 Jul 11. doi: 10.2340/actadv.v102.2225. Online ahead of print.

 

T W Van Hal 1M L M MulderM H WeninkM C PaschF H J Van den HoogenJuul M P A Van den ReekElke M G J De Jong

48

Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities

Clin Exp Rheumatol. 2022 Jul;40(7):1267-1272. doi: 10.55563/clinexprheumatol/8zn9z8.Epub 2021 Jul 24.

 

George E Fragoulis 1Maria Pappa 2Gerasimos Evangelatos 2Alexios Iliopoulos 3Petros P Sfikakis 2Maria G Tektonidou 2

49

Investigation into the wait time for consultation in the psoriatic arthritis program

Clin Rheumatol. 2022 Jul 22. doi: 10.1007/s10067-022-06288-8. Online ahead of print.

 

Seiwon Park 1Orli M Silverberg 1Elham Moez 2 3Vinod Chandran 4Dafna D Gladman 5 6

50

Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

J Rheumatol. 2022 Jul;49(7):700-706. doi: 10.3899/jrheum.211033. Epub 2022 Apr 15.

 

Philip J Mease 1Taylor Blachley 2Blessing Dube 2Robert R McLean 2Nina Kim 3Peter Hur 4Alexis Ogdie 5

51

Effectiveness of Golimumab as Second Anti-TNFa Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study

J Clin Med. 2022 Jul 19;11(14):4178. doi: 10.3390/jcm11144178.

 

Salvatore D'Angelo 1Enrico Tirri 2Angela Maria Giardino 3Marco Mattucci-Cerinic 4 5Lorenzo Dagna 5Leonardo Santo 6Francesco Ciccia 7Bruno Frediani 8Marcello Govoni 9Francesca Bobbio Pallavicini 10Rosa Daniela Grembiale 11Andrea Delle Sedie 12Rita Mulè 13Francesco Paolo Cantatore 14Rosario Foti 15Elisa Gremese 16Paola Conigliaro 17Fausto Salaffi 18Ombretta Viapiana 19Alberto Cauli 20Roberto Giacomelli 21Luisa Arcarese 21Giuliana Guggino 22Romualdo Russo 23Amy Puenpatom 24Domenico Capocotta 2Francesca Nacci 25Maria Grazia Anelli 26Valentina Picerno 1Corrado Binetti 3Florenzo Iannone 26

52

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis

Dermatol Ther (Heidelb). 2022 Jul 21. doi: 10.1007/s13555-022-00770-6. Online ahead of print.

 

George Gondo 1Megan Mosca 2Julie Hong 2Emanual Maverakis 3Joseph F Merola 4April W Armstrong 5Tina Bhutani 2Stacie J Bell 6Wilson Liao 7

53

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Nat Rev Rheumatol. 2022 Jun 27;1-15. doi: 10.1038/s41584-022-00798-0.Online ahead of print.

 

Laura C Coates 1Enrique R Soriano 2Nadia Corp 3Heidi Bertheussen 4Kristina Callis Duffin 5Cristiano B Campanholo 6Jeffrey Chau 7Lihi Eder 8Daniel G Fernández-Ávila 9Oliver FitzGerald 10Amit Garg 11Dafna D Gladman 12Niti Goel 13Philip S Helliwell 14M Elaine Husni 15Deepak R Jadon 16Arnon Katz 17Dhruvkumar Laheru 18John Latella 19Ying-Ying Leung 20Christine Lindsay 21Ennio Lubrano 22Luis Daniel Mazzuoccolo 23Philip J Mease 24Denis O'Sullivan 25Alexis Ogdie 26Wendy Olsder 27Penelope Esther Palominos 28Lori Schick 29Ingrid Steinkoenig 30Maarten de Wit 31D A van der Windt 3Arthur Kavanaugh 32

54

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

RMD Open. 2022 Jun;8(2):e002286. doi: 10.1136/rmdopen-2022-002286.

 

Andrew J K Ostor 1Ahmed M Soliman 2Kim A Papp 3Byron Padilla 2Zailong Wang 2Ann Eldred 2Kurt de Vlam 4Alan Kivitz 5

55

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

Ann Rheum Dis. 2022 Jul;81(7):944-950.doi: 10.1136/annrheumdis-2021-222027. Epub 2022 Apr 7.

 

Atul A Deodhar 1Bernard Combe 2Ana P Accioly 3Rebecca Bolce 4Danting Zhu 3Amanda M Gellett 3Aubrey Trevelin Sprabery 3Gerd-Rüdiger R Burmester 5

56

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

RMD Open. 2022 Jun;8(2):e002167. doi: 10.1136/rmdopen-2021-002167.

 

James M Gwinnutt 1Maud Wieczorek 2 3Javier Rodríguez-Carrio 4 5Andra Balanescu 6Heike A Bischoff-Ferrari 3 7 8Annelies Boonen 9 10Giulio Cavalli 11Savia de Souza 12Annette de Thurah 13 14Thomas E Dorner 15 16 17Rikke Helene Moe 18Polina Putrik 9 10Lucía Silva-Fernández 19Tanja Stamm 20 21Karen Walker-Bone 22Joep Welling 23Mirjana Zlatkovic-Švenda 24 25Francis Guillemin 2 26Suzanne M M Verstappen 27 22 28

57

Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis

J Rheumatol. 2022 Jul;49(7):694-699. doi: 10.3899/jrheum.210906.Epub 2022 Apr 15.

 

Philip J Mease 1Arthur Kavanaugh 2Alexis Ogdie 3Alvin F Wells 4Martin Bergman 5Dafna D Gladman 6Sven Richter 7Lichen Teng 7Shauna Jardon 7Josef S Smolen 8

58

Psoriatic arthritis: Ultrasound peculiarities with particular emphasis on enthesitis

J Clin Ultrasound. 2022 May;50(4):556-560. doi: 10.1002/jcu.23170.Epub 2022 Mar 2.

 

Ferdinando Draghi 1 2Guia Ferrozzi 3 4Daniela Ballerini 5Chandra Bortolotto 5

59

A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis

J Dermatolog Treat. 2022 Jun;33(4):1907-1915.doi: 10.1080/09546634.2021.1942423. Epub 2021 Jun 28.

 

Alice B Gottlieb 1Joseph F Merola 2

60

Psoriatic arthritis from a mechanistic perspective

Nat Rev Rheumatol. 2022 Jun;18(6):311-325. doi: 10.1038/s41584-022-00776-6.Epub 2022 May 5.

 

Georg Schett 1 2Proton Rahman 3Christopher Ritchlin 4Iain B McInnes 5Dirk Elewaut 6Jose U Scher 7

61

New Insights on Juvenile Psoriatic Arthritis

Front Pediatr. 2022 May 26;10:884727. doi: 10.3389/fped.2022.884727.eCollection 2022.

 

Francesco Brunello 1Francesca Tirelli 1Luca Pegoraro 1Filippo Dell'Apa 1Alessandra Alfisi 1Giulia Calzamatta 1Camilla Folisi 1Francesco Zulian 1

62

Apremilast Use in Oligoarticular Psoriatic Arthritis

J Rheumatol. 2022 Jun 1;jrheum.211227. doi: 10.3899/jrheum.211227. Online ahead of print.

 

Vicenç Torrente-Segarra 1Maria Bonet 1

63

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

Rheumatol Ther. 2022 Apr;9(2):521-539. doi: 10.1007/s40744-021-00410-z. Epub 2021 Dec 30.

 

Gerd R Burmester 1Kevin Winthrop 2Ricardo Blanco 3Peter Nash 4Philippe Goupille 5Valderilio F Azevedo 6Carlo Salvarani 7Andrea Rubbert-Roth 8Elizabeth Lesser 9Ralph Lippe 10Apinya Lertratanakul 9Reva M Mccaskill 9John Liu 9Eric M Ruderman 11

64

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Semin Arthritis Rheum. 2022 Apr;53:151979. doi: 10.1016/j.semarthrit.2022.151979.Epub 2022 Feb 9.

 

Alexander Egeberg 1Nana Aviaaja Lippert Rosenø 2David Aagaard 2Erik Hillo Lørup 2Mia-Louise Nielsen 2Lea Nymand 2Lars Erik Kristensen 3Jacob P Thyssen 2Simon Francis Thomsen 2Rene Lindholm Cordtz 4Nikolai Loft 5Lone Skov 6Lars Erik Bryld 7Mads Kirchheiner Rasmussen 8Pil Højgaard 9Salome Kristensen 4Lene Dreyer 10

65

Sex-Based Medicine Meets Psoriatic Arthritis: Lessons Learned and to Learn

Front Immunol. 2022 Apr 22;13:849560. doi: 10.3389/fimmu.2022.849560.eCollection 2022.

 

Nicola Luigi Bragazzi 1 2 3Charlie Bridgewood 3Abdulla Watad 3 4 5Giovanni Damiani 6Dennis McGonagle 3 7

66

Real-life efficacy of guselkumab in patients with early psoriatic arthritis

Rheumatology (Oxford). 2022 Mar 2;61(3):1217-1221.doi: 10.1093/rheumatology/keab509.

 

Ilenia Pantano 1Daniele Mauro 1Francesca Romano 2Alessio Gambardella 2Mario Valenti 3 4Davide Simone 1Daniela Iacono 1Antonio Costanzo 3 4Giuseppe Argenziano 2Francesco Ciccia 1

67

Advances of Genomic Medicine in Psoriatic Arthritis

J Pers Med. 2022 Jan 3;12(1):35. doi: 10.3390/jpm12010035.

 

Carlos M Laborde 1Leyre Larzabal 1Álvaro González-Cantero 2 3Patricia Castro-Santos 4Roberto Díaz-Peña 5

68

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Ann Rheum Dis. 2022 Jun;81(6):815-822.doi: 10.1136/annrheumdis-2021-221664. Epub 2022 Mar 3.

 

Philip J Mease 1Atul A Deodhar 2Désirée van der Heijde 3Frank Behrens 4Alan J Kivitz 5Jeffrey Neal 6Jonghyeon Kim 7Shalabh Singhal 7Miroslawa Nowak 7Subhashis Banerjee 7

69

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials

Clin Rheumatol. 2022 Feb;41(2):499-511. doi: 10.1007/s10067-021-05894-2.Epub 2021 Sep 12.

 

Alan J Kivitz 1Oliver FitzGerald 2Peter Nash 3Shirley Pang 4Valderilio F Azevedo 5Cunshan Wang 6Liza Takiya 7

70

Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence

Rheumatol Ther. 2022 Jun;9(3):803-821. doi: 10.1007/s40744-022-00443-y.Epub 2022 Apr 12.

 

Laura C Coates 1Maarten de Wit 2Amy Buchanan-Hughes 3Maartje Smulders 4 5Anna Sheahan 6Alexis R Ogdie 7

71

Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis

Dermatology. 2022 May 12;1-12. doi: 10.1159/000524231.Online ahead of print.

 

Juliëtte N Pouw 1 2Marleen E Jacobs 1Deepak M W Balak 3Jacob M van Laar 1Paco M J Welsing 1Emmerik F A Leijten 1 2

72

Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis

Rheumatology (Oxford). 2022 Apr 11;61(4):1328-1340.doi: 10.1093/rheumatology/keab774.

 

Gian Luca Erre 1 2Dimitris Mavridis 3Richard John Woodman 4Arduino Aleksander Mangoni 5 6

73

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Lancet. 2021 Nov 27;398(10315):1984-1996.doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9.

 

Nicolino Ruperto 1Hermine I Brunner 2Olga Synoverska 3Tracy V Ting 2Carlos Abud Mendoza 4Alberto Spindler 5Yulia Vyzhga 6Katherine Marzan 7Lyudmila Grebenkina 8Irit Tirosh 9Lisa Imundo 10Rita Jerath 11Daniel J Kingsbury 12Betul Sozeri 13Sheetal S Vora 14Sampath Prahalad 15Elena Zholobova 16Yonatan Butbul Aviel 17Vyacheslav Chasnyk 18Melissa Lerman 19Kabita Nanda 20Heinrike Schmeling 21Heather Tory 22Yosef Uziel 23Diego O Viola 24Holly B Posner 25Keith S Kanik 26Ann Wouters 25Cheng Chang 26Richard Zhang 25Irina Lazariciu 25Ming-Ann Hsu 26Ricardo M Suehiro 27Alberto Martini 28Daniel J Lovell 2Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

Collaborators

Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG): 

R CutticaJ AkikusaJ ChaitowC WoutersS OliveiraCls NeivaM SantiagoC A SilvaM T TerreriC MagalhaesV De SouzaM BandeiraG ChédevilleK HoughtonM Vazquez-Del MercadoJ Rizo RodriguezK KobusinskaE AlexeevaI Calvo PenadesA L BoteanuO KasapcopurM H PoyrazogluM ErguvenS OzenE Al-AbadiJ BohnsackR CarrascoJ DareB GottliebD WaheziL JungM Klein-GitelmanY ZhangL Wagner-WeinerS TarvinR K VeheP ChiraseveenuprapundR Rivas-ChaconW De La PenaAcp Sagcal-GironellaJ E Weiss

74

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE

Rheumatology (Oxford). 2022 May 5;61(5):1867-1876.doi: 10.1093/rheumatology/keab628.

 

Maria Antonietta D'Agostino 1Georg Schett 2 3Alejandra López-Rdz 4Ladislav Šenolt 5Katalin Fazekas 6Ruben Burgos-Vargas 7Jose Maldonado-Cocco 8Esperanza Naredo 9Philippe Carron 10 11Anne-Marie Duggan 12Punit Goyanka 13Maarten Boers 14Corine Gaillez 15

75

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Ann Rheum Dis. 2022 Mar;81(3):351-358.doi: 10.1136/annrheumdis-2021-221048. Epub 2021 Nov 23.

 

Andrew Östör 1Filip Van den Bosch 2Kim Papp 3Cecilia Asnal 4Ricardo Blanco 5Jacob Aelion 6Gabriela Alperovich 7Wenjing Lu 7Zailong Wang 7Ahmed M Soliman 7Ann Eldred 7Lisa Barcomb 7Alan Kivitz 8 9

76

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Ann Rheum Dis. 2022 Feb;81(2):225-231.doi: 10.1136/annrheumdis-2021-221019. Epub 2021 Dec 15.

 

Lars Erik Kristensen 1Mauro Keiserman 2Kim Papp 3Leslie McCasland 4Douglas White 5Wenjing Lu 6Zailong Wang 6Ahmed M Soliman 6Ann Eldred 6Lisa Barcomb 6Frank Behrens 7

77

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Ann Rheum Dis. 2022 Mar;81(3):359-369.doi: 10.1136/annrheumdis-2021-220991. Epub 2021 Nov 24.

 

Laura C Coates 1Laure Gossec 2 3Elke Theander 4Paul Bergmans 5Marlies Neuhold 6Chetan S Karyekar 7May Shawi 8Wim Noël 6Georg Schett 9Iain B McInnes 10

78

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis

J Rheumatol. 2021 Dec;48(12):1815-1823. doi: 10.3899/jrheum.201532.Epub 2021 May 1.

 

Proton Rahman 1Christopher T Ritchlin 2Philip S Helliwell 3Wolf-Henning Boehncke 4Philip J Mease 5Alice B Gottlieb 6Shelly Kafka 7Alexa P Kollmeier 8Elizabeth C Hsia 9Xie L Xu 8May Shawi 10Shihong Sheng 11Prasheen Agarwal 11Bei Zhou 11Paraneedharan Ramachandran 11Yanli Zhuang 11Iain B McInnes 12

79

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies

Rheumatology (Oxford). 2021 Nov 3;60(11):5337-5350.doi: 10.1093/rheumatology/keab285.

 

Dennis McGonagle 1Iain B McInnes 2Atul Deodhar 3Georg Schett 4May Shawi 5Shelly Kafka 6Chetan S Karyekar 5Alexa P Kollmeier 7Elizabeth C Hsia 8 9Xie L Xu 7Shihong Sheng 10Prasheen Agarwal 10Bei Zhou 10Christopher T Ritchlin 11Proton Rahman 12Philip J Mease 13

80

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis

Arthritis Rheumatol. 2022 Mar;74(3):475-485. doi: 10.1002/art.42010.Epub 2022 Feb 7.

 

Iain B McInnes 1Proton Rahman 2Alice B Gottlieb 3Elizabeth C Hsia 4Alexa P Kollmeier 5Xie L Xu 5Yusang Jiang 6Shihong Sheng 6May Shawi 7Soumya D Chakravarty 8Désirée van der Heijde 9Philip J Mease 10

81

Association of Cardiac Biomarkers with Cardiovascular Outcomes in Patients with Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study

Arthritis Rheumatol. 2022 Mar 8. doi: 10.1002/art.42079. Online ahead of print.

 

Keith Colaco 1 2 3Ker-Ai Lee 4Shadi Akhtari 1 2Raz Winer 5Paul Welsh 6Naveed Sattar 6Iain B McInnes 6Vinod Chandran 2 3Paula Harvey 1 2Richard J Cook 4Dafna D Gladman 2 3Vincent Piguet 1 2Lihi Eder 1 2

82

Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients

Rheumatology (Oxford). 2022 Mar 2;61(3):1035-1043.doi: 10.1093/rheumatology/keab449.

 

Alvin F Wells 1Christopher J Edwards 2Alan J Kivitz 3Paul Bird 4Benoit Guerette 5Nikolay Delev 6Maria Paris 5Lichen Teng 5Jacob A Aelion 7

83

Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey

Rheumatol Ther. 2022 Mar 17. doi: 10.1007/s40744-022-00435-y. Online ahead of print.

Pascal Richette 1, Laura C Coates 2, Valderilio F Azevedo 3, Joseph C Cappelleri 4, Jade Moser 5, Ruben Queiro-Silva 6, Lara Fallon 7, Meriem Kessouri 8

84

Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis

J Rheumatol. 2022 Mar 15;jrheum.211329. doi: 10.3899/jrheum.211329. Online ahead of print.

Peter Nash 1

85

Psoriatic arthritis: prospects for the future

Ther Adv Musculoskelet Dis. 2022 Mar 28;14:1759720X221086710.doi: 10.1177/1759720X221086710. eCollection 2022.

Simon Hackett 1, Alexis Ogdie 2, Laura C Coates 3

86

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database

JAMA Dermatol. 2022 Mar 23. doi: 10.1001/jamadermatol.2022.0364. Online ahead of print.

Laura Pina Vegas 1 2, Laetitia Penso 1 3, Pascal Claudepierre 1 2, Emilie Sbidian 1 4 5

87

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes

RMD Open. 2022 Mar;8(1):e002074. doi: 10.1136/rmdopen-2021-002074.

Iain B McInnes 1, Laura M Sawyer 2, Kristen Markus 3, Corinne LeReun 4, Celia Sabry-Grant 3, Philip S Helliwell 5

88

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials

RMD Open. 2022 Mar;8(1):e002049. doi: 10.1136/rmdopen-2021-002049.

Iain B McInnes 1, Andrew J K Ostor 2 3, Philip J Mease 4, William Tillett 5, Xenofon Baraliakos 6, Kurt de Vlam 7, Louis Bessette 8, Ralph Lippe 9, Anna Maniccia 10, Dai Feng 10, Tianming Gao 10, Patrick Zueger 10, Christopher Saffore 10, Koji Kato 10, In-Ho Song 10, Atul Deodhar 11

89

Correlation of patient-reported routine assessment of patient index data with clinical measures of disease activity in psoriatic arthritis

Int J Rheum Dis. 2022 Mar 25. doi: 10.1111/1756-185X.14310. Online ahead of print.

Louise Ward 1, Michael Oliffe 2, Barry Kane 1, Diana Chessman 2, Donna Meaney 1, Fiona Briggs 2, Kathryn Gibson 2 3, Les Barnsley 1 4, Daniel Sumpton 1 5

90

Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis

Rheumatol Adv Pract. 2021 Nov 15;5(3):rkab086. doi: 10.1093/rap/rkab086. eCollection 2021.

Sayam R Dubash 1 2, Oras A Alabas 2 3, Xabier Michelena 2 4, Leticia Garcia-Montoya 1 2, Gabriele De Marco 1 2, Mira Merashli 5, Richard J Wakefield 1 2, Paul Emery 1 2, Dennis McGonagle 1 2, Ai Lyn Tan 1 2, Helena Marzo-Ortega 1 2

91

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

Joint Bone Spine. 2022 Jan 14;89(3):105344. doi: 10.1016/j.jbspin.2022.105344.Online ahead of print.

Daniel Wendling 1, Sophie Hecquet 2, Olivier Fogel 3, Jean-Guillaume Letarouilly 4, Frank Verhoeven 2, Thao Pham 5, Clément Prati 2, Anna Molto 6, Philippe Goupille 7, Emmanuelle Dernis 8, Alain Saraux 9, Adeline Ruyssen-Witrand 10, Cédric Lukas 11, Corinne Miceli-Richard 3, Christophe Hudry 12, Pascal Richette 13, Maxime Breban 14, Laure Gossec 15, Maxime Dougados 16, Pascal Claudepierre 17

92

Endometriosis, psoriasis and psoriatic arthritis: A prospective cohort study

Am J Epidemiol. 2022 Jan 13;kwac009. doi: 10.1093/aje/kwac009. Online ahead of print.

Holly R Harris 1 2, Karen Moreno Nascimento Korkes 3, Tricia Li 4 5, Marina Kvaskoff 6, Eunyoung Cho 4 5 7, Luiz Fernando Carvalho 3, Abrar A Qureshi 4 5 8, Mauricio Abrao 3 9, Stacey A Missmer 10 11

93

Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis

J Rheumatol. 2022 Feb 15;jrheum .211325. doi: 10.3899/jrheum.211325. Online ahead of print.

Deepak R Jadon 1, Arthur Kavanaugh 1, Ying Ying Leung 1

94

Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

J Rheumatol. 2022 Feb 15;jrheum.211317. doi: 10.3899/jrheum.211317. Online ahead of print.

Kristina Callis Duffin 1, Dafna D Gladman 1, Niti Goel 1, Alice B Gottlieb 1, Oliver FitzGerald 1, Lynne V McFarland 1

95

Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis

Rheumatol. 2022 Feb 15;jrheum.211321. doi: 10.3899/jrheum.211321. Online ahead of print.

Erik Lubberts 1, Jose U Scher 1, Oliver FitzGerald 1

96

Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group

J Rheumatol. 2022 Feb 15;jrheum.211322. doi: 10.3899/jrheum.211322. Online ahead of print.

Anna Antony 1, Richard Holland 1, Ashish J Mathew 1, Maria-Antoinetta D'Agostino 1, Walter P Maksymowych 1, Philip J Mease 1, Niti Goel 1, Alexis Ogdie 1, Laura C Coates 1, Vibeke Strand 1, Robin Christensen 1, Dafna D Gladman 1, Ana-Maria Orbai 1, Ying Ying Leung 1, William Tillett 1

97

Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis

 Clin Rheumatol. 2022 Mar 1;28(2):55-61. doi: 10.1097/RHU.0000000000001799.

Monica Schwartzman 1, Zafir Abutalib 2, Lisa A Mandl

98

COVID-19 hospitalizations, intensive care unit stays, ventilation and death among patients with immune mediated inflammatory diseases compared to controls

J Rheumatol. 2022 Feb 1;jrheum.211012. doi: 10.3899/jrheum.211012. Online ahead of print.

Lihi Eder 1Ruth Croxford 1Aaron M Drucker 1Arielle Mendel 1Bindee Kuriya 1Zahi Touma 1Sindhu R Johnson 1Richard Cook 1Sasha Bernatsky 1Nigil Haroon 1Jessica Widdifield 1

99

Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis

Clin Rheumatol. 2022 Jan 27. doi: 10.1007/s10067-021-06045-3. Online ahead of print.

Guy Katz 1Alexis Ogdie 2Joshua F Baker 3Michael D George 2

100

Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists

Clin Rheumatol. 2022 Jan 26;1-13. doi: 10.1007/s10067-022-06077-3.Online ahead of print.

Alice B Gottlieb 1Alvin F Wells 2Joseph F Merola 3

101

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia

BMC Rheumatol. 2022 Jan 27;6(1):5.doi: 10.1186/s41927-021-00235-x.

Anat Fisher 1Jason D Kim 2Greg Carney 2Colin Dormuth 2

102

Pregnancy, delivery, and neonatal outcomes among women with psoriatic arthritis, a population based study

J Perinat Med. 2022 Jan 21. doi: 10.1515/jpm-2021-0468. Online ahead of print.

Ella M Gangbe 1Ahmad Badeghiesh 2Haitham Baghlaf 3Michael H Dahan 4

103

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0.

Dafna D Gladman 1Laura C Coates 2Joseph Wu 3Lara Fallon 4Elizabeth D Bacci 5Joseph C Cappelleri 3Andrew G Bushmakin 3Philip S Helliwell 6

104

Impact of psoriatic disease on women aged 18 to 45: Results from a multinational survey across 11 European countries

Int J Womens Dermatol. 2021 Aug 28;7(5Part B):697-707. doi: 10.1016/j.ijwd.2021.08.011.eCollection 2021 Dec.

Sandy R McBride 1Maria C Fargnoli 2Anne-Claire Fougerousse 3Marta García Bustínduy 4Louise Catton 5Lerzan Senturk 6Cécile Ecoffet 6Jan Koren 7Laura Andreoli 8 9Laura C Coates 10Alice Titialii 11

105

Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis - data from the Danish nationwide DANBIO registry

Semin Arthritis Rheum. 2021 Dec 30;151948. doi: 10.1016/j.semarthrit.2021.12.012.Online ahead of print.

Ashish J Mathew 1Bente Glintborg 2Niels Steen Krogh 3Merete L Hetland 2Mikkel Østergaard 2

106

Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study

J Clin Med. 2021 Dec 29;11(1):180. doi: 10.3390/jcm11010180.

Antonio Marchesoni 1Pierluigi Macchioni 2Stefania Gasparini 3Carlo Perricone 4Fabio Massimo Perrotta 5Rosa Daniela Grembiale 6Ettore Silvagni 7Roberta Ramonda 8Luisa Costa 9Alen Zabotti 10Giacomo Curradi 11Giuliana Gualberti 11Francesca Marando 11Carlo Salvarani 2

107

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Ther Adv Musculoskelet Dis. 2021 Dec 18;13:1759720X211057975.doi: 10.1177/1759720X211057975. eCollection 2021.

Denis Poddubnyy 1Xenofon Baraliakos 2Filip Van den Bosch 3Jürgen Braun 2Laura C Coates 4Vinod Chandran 5Torsten Diekhoff 6Floris A van Gaalen 7Lianne S Gensler 8Niti Goel 9Alice B Gottlieb 10Désirée van der Heijde 7Philip S Helliwell 11Kay Geert A Hermann 6Deepak Jadon 12Robert G Lambert 13Walter P Maksymowych 14Philip Mease 15Peter Nash 16Fabian Proft 17Mikhail Protopopov 17Joachim Sieper 17Murat Torgutalp 17Dafna D Gladman 5

108

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response

Rheumatology (Oxford). 2021 Dec 23;keab945. doi: 10.1093/rheumatology/keab945.Online ahead of print.

Sara Nysom Christiansen 1Lykke Midtbøll Ørnbjerg 1Simon Horskjær Rasmussen 1Anne Gitte Loft 2 3Johan Askling 4Florenzo Iannone 5Jakub Zavada 6Brigitte Michelsen 1 7 8Michael Nissen 9Fatos Onen 10Maria Jose Santos 11Manuel Pombo-Suarez 12Heikki Relas 13Gary J Macfarlane 14Matija Tomsic 15Catalin Codreanu 16Bjorn Gudbjornsson 17Irene Van der Horst-Bruinsma 18Daniela Di Giuseppe 4Bente Glintborg 1 3Elisa Gremese 19Karel Pavelka 6Eirik Klami Kristianslund 7Adrian Ciurea 20Nurullah Akkoc 21Anabela Barcelos 22Carlos Sánchez-Piedra 23Ritva Peltomaa 13Gareth T Jones 14Ziga Rotar 15Ruxandra Ionescu 16Gerdur Grondal 24Marleen G H Van de Sande 25Karin Laas 26Mikkel Østergaard 1 27Merete L Hetland 1 3 27

109

Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease

Arthritis Care Res (Hoboken). 2021 Dec 10. doi: 10.1002/acr.24837. Online ahead of print.

Tiffany Dharia 1Shilpa Venkatachalam 2Joshua F Baker 1Shubhasree Banerjee 1David Curtis 2Maria I Danila 3Kelly Gavigan 2Jennifer Gordon 4Peter A Merkel 1Dianne G Shaw 5Kalen Young 5Jeffrey R Curtis 3William B Nowell 2Michael D George 1

110

Economic burden of joint analysis in psoriasis: US claims analysis

Am J Manag Care. 2021 Dec 1;27(12):e406-e412. doi: 10.37765/ajmc.2021.88768.

Patricia Prince 1Michelle SkornickiRobert SurukiEdward LeeAnthony Louder

111

The relationship between the nail and systemic enthesitis in psoriatic arthritis

Rheumatol Adv Pract. 2021 Nov 19;5(3):rkab088. doi: 10.1093/rap/rkab088. eCollection 2021.

Ashley Elliott 1Adrian Pendleton 2Gary Wright 2Madeleine Rooney 1

112

Evolution of patient characteristics in the era of biologic treatment of psoriatic arthritis: 18-year Belgian experience from the Leuven Spondyloarthritis Biologics Cohort (BioSPAR)

Rheumatol Adv Pract. 2021 Nov 15;5(3):rkab085.

doi: 10.1093/rap/rkab085. eCollection 2021.

Alla Ishchenko 1 2Johan Joly 2Barbara Neerinckx 1 2Rik Lories 1 2Kurt de Vlam 1 2

113

The Digital Way to Intercept Psoriatic Arthritis

Front Med (Lausanne). 2021 Nov 23;8:792972. doi: 10.3389/fmed.2021.792972.eCollection 2021.

Ivan Giovannini 1Philipp Bosch 2Christian Dejaco 3Gabriele De Marco 4Dennis McGonagle 4Luca Quartuccio 1Salvatore De Vita 1Enzo Errichetti 5Alen Zabotti 1

114

COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance

J Rheumatol. 2021 Sep 1;jrheum.210480. doi: 10.3899/jrheum.210480. Online ahead of print.

Bonnie L Bermas 1Milena Gianfrancesco 1Helen L Tanner 1Andrea M Seet 1Mathia C Aguiar 1Nasra K Al Adhoubi 1Samar Al Emadi 1Bernardo M Cunha 1Rachael Flood 1Daria A Kusevich 1Eoghan M McCarthy 1Naomi J Patel 1Eric Ruderman 1Sebastian E Sattui 1Savino Sciascia 1Faizah Siddique 1Maria O Valenzuela-Almada 1Leanna M Wise 1Angus B Worthing 1JoAnn Zell 1Suleman Bhana 1Wendy Costello 1Ali Duarte-Garcia 1Rebecca Grainger 1Laure Gossec 1Jonathan S Hausmann 1Kimme Hyrich 1Saskia Lawson-Tovey 1Jean W Liew 1Emily Sirotich 1Jeffrey A Sparks 1Paul Sufka 1Zachary S Wallace 1Pedro M Machado 1Anja Strangfeld 1Megan E B Clowse 1Jinoos Yazdany 

115

Digital Approaches for a Reliable Early Diagnosis of Psoriatic Arthritis

Front Med (Lausanne). 2021 Aug 11;8:718922. doi: 10.3389/fmed.2021.718922.eCollection 2021.

Filippo Fagni 1 2Johannes Knitza 1 2Martin Krusche 3Arnd Kleyer 1 2Koray Tascilar 1 2David Simon 1 2

116

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study

Arthritis Rheumatol. 2021 Aug 23. doi: 10.1002/art.41946. Online ahead of print.

Yael Shalev Rosenthal 1Naama Schwartz 2Iftach Sagy 3 4Lev Pavlovsky 1 5

117

PsAID High-impact Disease in Psoriatic Arthritis: A Component Weighting Analysis of the Assessment of SpondyloArthritis international Society Health Index

J Rheumatol. 2021 Aug 15;jrheum.210377. doi: 10.3899/jrheum.210377. Online ahead of print.

Rubén Queiro 1Isla Morante 1

118

Employment and Functional Ability in Men and Women With Axial Spondyloarthritis as Described in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry

J Rheumatol. 2021 Sep 1;jrheum.210469. doi: 10.3899/jrheum.210469. Online ahead of print.

Sinead Maguire 1Gillian Fitzgerald 1Finbar O'Shea 1

119

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores

Clin Trials. 2021 Aug 25;17407745211023840. doi: 10.1177/17407745211023840.Online ahead of print.

Sarah M Weinstein 1Laura C Coates 2Philip S Helliwell 3Alexis Ogdie 1 4Alisa J Stephens-Shields 1

120

Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results

J Rheumatol. 2021 May;48(5):693-697. doi: 10.3899/jrheum.191209. Epub 2020 Nov 15.

Alexis Ogdie 1Mei Liu 2Meghan Glynn 2Kelechi Emeanuru 2Leslie R Harrold 3Sven Richter 4Benoit Guerette 4Philip J Mease 5

121

Risk of Osteoarthritis in an Incident Cohort of People With Psoriatic Arthritis: A Population-based Cohort Study

J Rheumatol. 2021 Jun;48(6):841-846. doi: 10.3899/jrheum.200564. Epub 2020 Nov 15.

Rachel A Charlton 1Amelia Green 1Gavin Shaddick 2Julia Snowball 1Alison Nightingale 1William Tillett 3Catherine Smith 4Neil J McHughPROMPT Study Group

122

Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database

Drugs Real World Outcomes. 2021 Mar;8(1):29-38. doi: 10.1007/s40801-020-00217-4.Epub 2020 Nov 12.

Peter Hur 1Nina Kim 2 3Dong Dai 4Olivia W Piao 5Josh Z Zheng 5Esther Yi 4

123

Does age matter in Psoriatic arthritis? A narrative review

J Rheumatol. 2021 Aug 15;jrheum.210349. doi: 10.3899/jrheum.210349. Online ahead of print.

George E Fragoulis 1Elena Nikiphorou 1Iain B McInnes 1Stefan Siebert 1

124

Are fatty acids associated with disease activity and biomarkers in patients with psoriatic arthritis? Data from a multicenter clinical trial

Rheumatol Int. 2021 Jul 29. doi: 10.1007/s00296-021-04953-w. Online ahead of print.

Salome Kristensen 1 2Signe Holm Nielsen 3 4Erik Berg Schmidt 5 6Anne Christine Bay-Jensen 3Morten A Karsdal 3Jeppe Hagstrup Christensen 5 7

125

Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study

ACR Open Rheumatol. 2020 Nov;2(11):640-647. doi: 10.1002/acr2.11180. Epub 2020 Oct 19.

Philip Mease 1M Elaine Husni 2Soumya D Chakravarty 3Shelly Kafka 4Dennis Parenti 4Lilianne Kim 5Kim Hung Lo 5Elizabeth C Hsia 6Arthur Kavanaugh 7

126

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Ann Rheum Dis. 2021 Feb;80(2):185-193.doi: 10.1136/annrheumdis-2019-216835. Epub 2020 Oct 26.

Philip J Mease 1Philip S Helliwell 2Kasper Fjellhaugen Hjuler 3Kyle Raymond 4Iain McInnes 5

127

Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity - a cross-sectional study

Rheumatology (Oxford). 2021 Apr 6;60(4):1858-1862. doi: 10.1093/rheumatology/keaa604.

Lyn D Ferguson 1Jennifer Linge 2 3Olof Dahlqvist Leinhard 2 3Rosemary Woodward 4Pauline Hall Barrientos 4Giles Roditi 4Aleksandra Radjenovic 1Iain B McInnes 5Stefan Siebert 5Naveed Sattar 1

128

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600.

Philip J Mease 1Robert Landewé 2 3Proton Rahman 4Hasan Tahir 5Atul Singhal 6Elke Boettcher 7Sandra Navarra 8Aimee Readie 9Shephard Mpofu 10Eumorphia Maria Delicha 10Luminita Pricop 9Desirée van der Heijde 11

129

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

Curr Ther Res Clin Exp. 2020 Aug 12;93:100601. doi: 10.1016/j.curtheres.2020.100601.eCollection 2020.

Dafna D Gladman 1Ana-Maria Orbai 2Juan Gomez-Reino 3Stacey Chang-Douglass 4Emanuele Leoncini 4Hannah E Burton 4Keith S Kanik 5Ana Belen Romero 6Joseph C Cappelleri 5Ming-Ann Hsu 5

130

Multimorbidity and comorbidity in psoriatic arthritis - a perspective

Expert Rev Clin Immunol. 2020 Oct;16(10):963-972 doi:10.1080/1744666X.2021.1825941.Epub 2020 Oct 3.

Ennio Lubrano 1Silvia Scriffignano 1Fabio Massimo Perrotta 1

131

Linking the patient experience of foot involvement related to psoriatic arthritis to the International Classification of Functioning, Disability and Health

Rheumatol Adv Pract. 2020 Jul 11;4(2):rkaa028. doi: 10.1093/rap/rkaa028. eCollection 2020.

Kate Carter 1Caterina Tannous 2Steven Walmsley 1Keith Rome 3Deborah E Turner 1 4

132

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

ACR Open Rheumatol. 2020 Oct;2(10):543-554. doi: 10.1002/acr2.11166. Epub 2020 Sep 10.

Christopher T Ritchlin 1Jon T Giles 2Alexis Ogdie 3Juan J Gomez-Reino 4Philip Helliwell 5Pamela Young 6Cunshan Wang 7Joseph Wu 7Ana Belén Romero 8John Woolcott 6Lori Stockert 6

133

Histological Evaluation of the Relationships Between Distal Interphalangeal Psoriatic Arthritis and Nail Psoriasis: Correlations With Anatomical Studies of the Normal Nail Unit and the Main Radiological Data Concerning Distal Interphalangeal Psoriatic Arthritis

Am J Dermatopathol. 2020 Dec;42(12):911-915. doi: 10.1097/DAD.0000000000001786.

Christophe Perrin 1 2

134

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis

Rheumatology (Oxford). 2021 Mar 2;60(3):1137-1147. doi: 10.1093/rheumatology/keaa271.

Laura C Coates 1Joseph F Merola 2Philip J Mease 3Alexis Ogdie 4Dafna D Gladman 5Vibeke Strand 6Leonieke J J van Mens 7Lyrica Liu 8Priscilla K Yen 9David H Collier 10Gregory Kricorian 10James B Chung 10Philip S Helliwell 11

135

Barriers to shared decision-making with women of reproductive age affected by a chronic inflammatory disease: a mixed-methods needs assessment of dermatologists and rheumatologists

BMJ Open. 2021 Jun 16;11(6):e043960. doi: 10.1136/bmjopen-2020-043960.

Suzanne Murray 1Monica Augustyniak 2Jenny E Murase 3 4Rebecca Fischer-Betz 5Catherine Nelson-Piercy 6Morgan Peniuta 2Ivo Vlaev 7

136

Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFa, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study

Clin Rheumatol. 2021 Jun 16. doi: 10.1007/s10067-021-05799-0. Online ahead of print.

Mariagrazia Lorenzin # 1Augusta Ortolan # 1Giacomo Cozzi 1Antonia Calligaro 1Maria Favaro 1Teresa Del Ross 1Andrea Doria 1Roberta Ramonda 2

137

Measurement of minimal disease activity in psoriatic arthritis using PROMIS-Physical Function or the Health Assessment Questionnaire-Disability Index

Arthritis Care Res (Hoboken). 2020 Aug 29;10.1002/acr.24433. doi: 10.1002/acr.24433.Online ahead of print.

Erin Chew 1 2Jamie Perin 3Thomas Grader-Beck 1Ana-Maria Orbai 1

138

Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates

Arthritis Res Ther. 2020 Aug 26;22(1):198. doi: 10.1186/s13075-020-02294-w.

Glenn Haugeberg 1 2Mari Hoff 3Arthur Kavanaugh 4Brigitte Michelsen 5

139

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

Ann Rheum Dis. 2021 Jun 3;annrheumdis-2021-220097.doi: 10.1136/annrheumdis-2021-220097. Online ahead of print.

Ulf Lindström 1Daniela Di Giuseppe 2Bénédicte Delcoigne 2Bente Glintborg 3 4Burkhard Möller 5Adrian Ciurea 6Manuel Pombo-Suarez 7Carlos Sanchez-Piedra 8Kari Eklund 9 10Heikki Relas 9Bjorn Gudbjornsson 11 12Thorvardur Jon Love 12 13Gareth T Jones 14Catalin Codreanu 15Ruxandra Ionescu 16Lucie Nekvindova 17 18Jakub Závada 19 20Nuh Atas 21Servet Yolbas 22Karen Minde Fagerli 23Brigitte Michelsen 23 24Žiga Rotar 25 26Matija Tomšic 25 26Florenzo Iannone 27Maria Jose Santos 28Pedro Avila-Ribeiro 29 30Lykke Midtbøll Ørnbjerg 31Mikkel Østergaard 31 32Lennart Th Jacobsson 33Johan Askling 2Michael J Nissen 34

140

Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis

Int J Rheum Dis. 2021 Jun 2. doi: 10.1111/1756-185X.14147. Online ahead of print.

Aravinthan Loganathan 1 2 3Narainraj Kamalaraj 1 4Carlos El-Haddad 1Kevin Pile 1 3

141

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting

J Rheumatol Suppl. 2021 Jun;97:65-66. doi: 10.3899/jrheum.201681.

Laura C Coates 1Nadia Corp 2Danielle A van der Windt 2Enrique R Soriano 3Arthur Kavanaugh 4

142

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting

J Rheumatol Suppl. 2021 Jun;97:64. doi: 10.3899/jrheum.201680.

Denis P O'Sullivan 1Ingrid Steinkoenig 2

143

Development of a national survey on foot involvement among people with psoriatic arthritis in Australia using a best practice approach: a survey development protocol

J Foot Ankle Res. 2020 Aug 26;13(1):53. doi: 10.1186/s13047-020-00424-w.

Kate Carter 1Steven Walmsley 2Keith Rome 3Deborah E Turner 4

144

Development and Validation of a Sonographic Enthesitis Instrument in Psoriatic Arthritis: The GRAPPA Diagnostic Ultrasound Enthesitis Tool (DUET) Project

J Rheumatol Suppl. 2020 Jun;96:50-52. doi: 10.3899/jrheum.200128.

Lihi Eder 1 2Gurjit S Kaeley 3 4Sibel Zehra Aydin 3 4

145

JAK inhibitors, Psoriatic Arthritis, and Axial Spondyloarthritis: a Critical Review of Clinical Trials

Expert Rev Clin Immunol. 2021 May 4. doi: 10.1080/1744666X.2021.1925541.Online ahead of print.

Stephanie Keeling 1Walter P Maksymowych 1

146

Updated therapies for the management of Psoriatic Arthritis

Clin Immunol. 2020 Nov;220:108536. doi: 10.1016/j.clim.2020.108536.Epub 2020 Jul 16.

Atrin Toussi 1Natalia Maverakis 2Stephanie T Le 3Soumajyoti Sarkar 4Smriti K Raychaudhuri 5Siba P Raychaudhuri 6

147

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis

J Rheumatol. 2021 Apr 15;jrheum.210175. doi: 10.3899/jrheum.210175. Online ahead of print.

Ying Ying Leung 1William Tillett 1Pil Hojgaard 1Ana-Maria Orbai 1Richard Holland 1Ashish J Mathew 1Niti Goel 1Jeffrey Chau 1Chris Lindsay 1Alexis Ogdie 1Laura C Coates 1Robin Christensen 1Philip Mease 1Vibeke Strand 1Dafna D Gladman 1

148

Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes

Semin Arthritis Rheum. 2021 Apr 15;51(3):530-538.doi: 10.1016/j.semarthrit.2021.04.003. Online ahead of print.

Yvette Meissner 1Tatjana Rudi 2Rebecca Fischer-Betz 3Anja Strangfeld 2

149

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

Br J Dermatol. 2021 Apr 8. doi: 10.1111/bjd.20136. Online ahead of print.

M Lebwohl 1A Deodhar 2C E M Griffiths 3M A Menter 4D Poddubnyy 5W Bao 6V Jehl 7K Marfo 7P Primatesta 7A Shete 7V Trivedi 6P J Mease 8

150

GRAPPA Treatment Recommendations: Updates and Methods

J Rheumatol Suppl. 2020 Jun;96:41-45. doi: 10.3899/jrheum.200126.

Arthur Kavanaugh 1 2Laura C Coates 3 4Danielle A van der Windt 3 4Nadia Corp 3 4Enrique R Soriano 3 4

151

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Rheumatol Ther. 2020 Sep;7(3):553-580.doi: 10.1007/s40744-020-00209-4. Epub 2020 Jun 6.

Peter Nash 1Laura C Coates 2Alan J Kivitz 3Philip J Mease 4Dafna D Gladman 5José A Covarrubias-Cobos 6Oliver FitzGerald 7Dona Fleishaker 8Cunshan Wang 8Joseph Wu 8Ming-Ann Hsu 8Sujatha Menon 8Lara Fallon 9Ana Belén Romero 10Keith S Kanik 8

152

Methotrexate in Psoriasis and Psoriatic Arthritis

J Rheumatol Suppl. 2020 Jun;96:31-35. doi: 10.3899/jrheum.200124.

Laura C Coates 1 2 3Joseph F Merola 4 5 6Suzanne M Grieb 4 5 6Philip J Mease 4 5 6Kristina Callis Duffin 4 5 6

153

Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies

Rheumatology (Oxford). 2021 Apr 6;keab285. doi: 10.1093/rheumatology/keab285.Online ahead of print.

Dennis McGonagle 1Iain B McInnes 2Atul Deodhar 3Georg Schett 4May Shawi 5Shelly Kafka 6Chetan S Karyekar 5Alexa P Kollmeier 7Elizabeth C Hsia 7 8Xie L Xu 7Shihong Sheng 9Prasheen Agarwal 9Bei Zhou 9Christopher T Ritchlin 10Proton Rahman 11Philip J Mease 12

154

Current treatments and recommendations

Best Pract Res Clin Rheumatol. 2021 Apr 3;101680. doi: 10.1016/j.berh.2021.101680.Online ahead of print.

Arani Vivekanantham 1Dylan McGagh 2Laura C Coates 3

155

Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real-world Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry

J Rheumatol. 2020 Jun 1;jrheum.191117. doi: 10.3899/jrheum.191117. Online ahead of print.

Philip J Mease 1Mei Liu 1Sabrina Rebello 1Winnie Hua 1Robert R McLean 1Peter Hur 1Alexis Ogdie 1

156

Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment?

Dermatol Ther. 2020 Sep;33(5):e13743. doi: 10.1111/dth.13743. Epub 2020 Jun 30.

Uwe Wollina 1Massimo Fioranelli 2Mohamad Goldust 3 4 5Torello Lotti 6

157

Not your average joint: Towards precision medicine in psoriatic arthritis

Clin Immunol. 2020 Aug;217:108470. doi: 10.1016/j.clim.2020.108470.Epub 2020 May 28.

Rochelle Castillo 1Jose U Scher 2

158

Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis

J Psoriasis Psoriatic Arthritis. 2020 Apr;5(2):61-67. doi: 10.1177/2475530320910814.Epub 2020 Mar 4.

Mary Patricia Smith 1Karen Ly 1Quinn Thibodeaux 1Kristen Beck 1Eric Yang 1 2Isabelle Sanchez 1 3Joanne Nititham 1Tina Bhutani 1Wilson Liao 1

159

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis

PLoS One. 2020 May 27;15(5):e0233781. doi: 10.1371/journal.pone.0233781.eCollection 2020.

Johan Burisch 1Wolfgang Eigner 2Stefan Schreiber 3Daniel Aletaha 4Wolfgang Weninger 5Michael Trauner 2Walter Reinisch 2Neeraj Narula 6

160

Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States

J Manag Care Spec Pharm. 2020 Aug;26(8):1027-1038. doi: 10.18553/jmcp.2020.19319.Epub 2020 Apr 20.

George Bungey 1Stacey Chang-Douglass 1Ming-Ann Hsu 2Joseph C Cappelleri 2Pamela Young 3John Woolcott 3

161

Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies

Curr Med Res Opin. 2020 Jul;36(7):1245-1252. doi: 10.1080/03007995.2020.1754186.Epub 2020 Apr 23.

Jessica A Walsh 1Qian Cai 2Iris Lin 3Timothy Fitzgerald 3Christopher D Pericone 2Soumya D Chakravarty 3 4

162

Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases

J Rheumatol. 2021 Jan 1;48(1):48-57. doi: 10.3899/jrheum.190815. Epub 2020 Apr 1.

Matthew L Thomas 1Gavin Shaddick 2Rachel Charlton 3Charlotte Cavill 4Richard Holland 4Florenzo Iannone 5Giovanni Lapadula 5Simona Lopriore 5Jakub Závada 6Michal Uher 7Karel Pavelka 6Lenka Szczuková 7Prodromos Sidiropoulos 8Irini Flouri 8Alexandros Drosos 9Burkhard Möller 10Michael J Nissen 11Rüdiger B Müller 12Almut Scherer 13Neil McHugh 14Alison Nightingale 15

163

Psoriatic arthritis in childhood: A commentary on the controversy

Clin Immunol. 2020 May;214:108396. doi: 10.1016/j.clim.2020.108396.Epub 2020 Mar 27.

Matthew L Stoll 1Elizabeth D Mellins 2

164

Challenges in the clinical diagnosis of psoriatic arthritis

Clin Immunol. 2020 May;214:108390. doi: 10.1016/j.clim.2020.108390.Epub 2020 Mar 18.

Mohamad Ali Rida 1Vinod Chandran 2

165

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Lancet. 2020 Apr 4;395(10230):1126-1136.doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13.

Philip J Mease 1Proton Rahman 2Alice B Gottlieb 3Alexa P Kollmeier 4Elizabeth C Hsia 5Xie L Xu 4Shihong Sheng 6Prasheen Agarwal 6Bei Zhou 6Yanli Zhuang 7Désirée van der Heijde 8Iain B McInnes 9DISCOVER-2 Study Group

166

Complexities in Genetics of Psoriatic Arthritis

Curr Rheumatol Rep. 2020 Mar 12;22(4):10. doi: 10.1007/s11926-020-0886-x.

Sara Rahmati 1 2Lam Tsoi 3Darren O'Rielly 1Vinod Chandran 1 2 4 5 6Proton Rahman 7

167

Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis

Rheumatology (Oxford). 2020 Sep 1;59(9):2199-2206.doi: 10.1093/rheumatology/keaa062.

Bradley Pittam 1Sonal Gupta 1Nicholas L Harrison 2Selina Robertson 1David M Hughes 3Sizheng Steven Zhao 2 4

168

The many faces of psoriatic arthritis: their genetic determinism

Rheumatology (Oxford). 2020 Mar 1;59(Suppl 1):i4-i9.doi: 10.1093/rheumatology/kez325.

Robert Winchester 1Oliver FitzGerald 2

169

Ixekizumab for the treatment of psoriasis: up-to-date

Expert Opin Biol Ther. 2020 Jun;20(6):549-557.doi: 10.1080/14712598.2020.1729736. Epub 2020 Mar 10.

Sarah Craig 1 2Richard B Warren 3

170

Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis

Rheumatol Int. 2020 Apr;40(4):511-521. doi: 10.1007/s00296-020-04526-3.Epub 2020 Feb 12.

Stephan Pflugbeil 1Karin Böckl 2Reinhold Pongratz 1Marianne Leitner 3Winfried Graninger 4Astrid Ortner 5

171

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Arthritis Res Ther. 2020 Mar 6;22(1):43. doi: 10.1186/s13075-020-2126-1.

Philip Mease 1, M Elaine Husni 2, Shelly Kafka 3, Soumya D Chakravarty 3 4, Diane D Harrison 5, Kim Hung Lo 5, Stephen Xu 5, Elizabeth C Hsia 5 6, Arthur Kavanaugh 7

172

Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015

J Rheumatol. 2020 Nov 1;47(11):1644-1651. doi: 10.3899/jrheum.190659. Epub 2020 Feb 15.

Lihi Eder 1, Jessica Widdifield 2, Cheryl F Rosen 3, Raed Alhusayen 4, Stephanie Y Cheng 5, Jacqueline Young 5, Willemina Campbell 6, Sasha Bernatsky 7, Dafna D Gladman 8, Michael Paterson 9, Karen Tu 10

173

Remission in psoriatic arthritis: Definition and predictors

Semin Arthritis Rheum. 2020 Dec;50(6):1494-1499. doi: 10.1016/j.semarthrit.2020.01.012.Epub 2020 Feb 3.

Samar Alharbi 1, Justine Y Ye 2, Ker-Ai Lee 3, Vinod Chandran 4, Richard J Cook 3, Dafna D Gladman 5